PRG Science & Technology Co., Ltd.
Study to Determine Optimal Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients with Hutchinson-Gilford Progeria Syndrome (HGPS)
Phase 2
Recruiting
- Conditions
- Hutchinson-Gilford Progeria Syndrome
- Interventions
- First Posted Date
- 2025-01-14
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- PRG Science & Technology Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT06775041
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
Phase 2, Open-Label Study to Evaluate the Safety and Tolerability of Progerinin in Werner Syndrome
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- PRG Science & Technology Co., Ltd.
- Target Recruit Count
- 5
- Registration Number
- NCT05847179
Phase I Study of Progerinin in Healthy Volunteers
Phase 1
Completed
- Conditions
- Hutchinson-Gilford Progeria SyndromeWerner Syndrome
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2021-09-22
- Lead Sponsor
- PRG Science & Technology Co., Ltd.
- Target Recruit Count
- 64
- Registration Number
- NCT04512963
- Locations
- 🇺🇸
PRG S&T Investigational Site, Glendale, California, United States
© Copyright 2025. All Rights Reserved by MedPath